• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Protein Cell >Current progress in innovative engineered antibodies
【2h】

Current progress in innovative engineered antibodies

机译：创新工程抗体的最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based molecules in phase III and phase I/II clinical trials, respectively. These total 719 antibody-based clinical stage molecules include 493 naked IgGs, 87 antibody-drug conjugates, 61 bispecific antibodies, 37 total Fc fusion proteins, 17 radioimmunoglobulins, 13 antibody fragments, and 11 immunocytokines. New uses for these antibodies are being discovered each year. For oncology, many of the exciting new approaches involve antibody modulation of T-cells. There are over 80 antibodies in clinical trials targeting T cell checkpoints, 26 T-cell-redirected bispecific antibodies, and 145 chimeric antigen receptor (CAR) cell-based candidates (all currently in phase I or II clinical trials), totaling more than 250 T cell interacting clinical stage antibody-based candidates. Finally, significant progress has been made recently on routes of delivery, including delivery of proteins across the blood-brain barrier, oral delivery to the gut, delivery to the cellular cytosol, and gene- and viral-based delivery of antibodies. Thus, there are currently at least 864 antibody-based clinical stage molecules or cells, with incredible diversity in how they are constructed and what activities they impart. These are followed by a next wave of novel molecules, approaches, and new methods and routes of delivery, demonstrating that the field of antibody-based biologics is very innovative and diverse in its approaches to fulfill their promise to treat unmet medical needs.
机译：截至2017年5月1日，已有74个基于抗体的分子被主要市场的监管机构批准。此外，在III期和I / II期临床试验中分别有70和575种基于抗体的分子。这些总共719个基于抗体的临床阶段分子包括493个裸IgG，87个抗体-药物偶联物，61个双特异性抗体，37个总Fc融合蛋白，17个放射免疫球蛋白，13个抗体片段和11种免疫细胞因子。每年都在发现这些抗体的新用途。对于肿瘤学，许多令人兴奋的新方法都涉及T细胞的抗体调节。在针对T细胞检查点的临床试验中，有80多种抗体，26种T细胞重定向的双特异性抗体和145种基于嵌合抗原受体（CAR）细胞的候选药物（目前均处于I或II期临床试验中），总计超过250种T细胞相互作用的临床阶段基于抗体的候选人。最后，最近在递送途径上取得了重大进展，包括跨血脑屏障的蛋白质递送，口服到肠道的递送，细胞胞质溶胶的递送以及基于基因和病毒的抗体的递送。因此，目前至少有864种基于抗体的临床阶段分子或细胞，其构建方式和赋予的活性具有令人难以置信的多样性。这些之后是下一波新分子，新方法，新方法和新的递送途径，这表明基于抗体的生物制剂领域在其方法上非常创新和多样化，可以满足他们对未满足的医疗需求的承诺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号